会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明授权
    • Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
    • 用于改善HIV gp41衍生肽的给药的药物组合物及其在治疗中的应用
    • US07045552B2
    • 2006-05-16
    • US10663589
    • 2003-09-16
    • David HeilmanJie DiBrian Bray
    • David HeilmanJie DiBrian Bray
    • A61K47/30
    • A61K9/0019A61K38/162A61K47/10A61K47/26
    • Provided is a pharmaceutical composition comprising a solution comprised of synthetic peptide in a final concentration of not less than 70 mg/ml in admixture with a polyol; wherein the synthetic peptide is an HIV fusion inhibitor, and wherein the polyol is in a final concentration of no less than 5 weight % and no more than 75 weight % of the pharmaceutical composition. Also provided is a synthetic peptide-containing pharmaceutical composition as a unit dose comprising an aqueous formulation comprised of synthetic peptide in a final concentration of not less than 70 mg/ml in admixture with a polyol; wherein the synthetic peptide is an HIV fusion inhibitor, and wherein the polyol is in a final concentration of no less than 5 weight % and no more than 75 weight % of the pharmaceutical composition. Further provided is a method of treating HIV infection by administering to an HIV-infected individual a pharmaceutical composition according to the present invention.
    • 本发明提供一种药物组合物,其包含与多元醇混合的终浓度不小于70mg / ml的合成肽的溶液; 其中所述合成肽是HIV融合抑制剂,并且其中所述多元醇的终浓度不低于所述药物组合物的5重量%且不大于75重量%。 还提供了含合成肽的药物组合物作为单位剂量,其包含由多元醇混合而成的最终浓度不小于70mg / ml的合成肽的水性制剂; 其中所述合成肽是HIV融合抑制剂,并且其中所述多元醇的终浓度不低于所述药物组合物的5重量%且不大于75重量%。 还提供了通过向HIV感染个体施用根据本发明的药物组合物来治疗HIV感染的方法。